Denosumab (Prolia & Xgeva) by Amgen Biosimilars Pipeline Review 2024: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic...

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA Prolia® (denosumab) is indicated to treat certain conditions that lead to high risk for fracture, including osteoporosis in postmenopausal womenTVB-009P, Teva’s proposed biosimilar to Prolia, showed...

Global Osteoporosis Disease Analysis Market Report 2020: Novartis has the Highest Number of Completed Clinical Trials for Osteoporosis with 120 Trials Dublin, Feb. 01, 2021 (GLOBE NEWSWIRE) -- The "Disease Analysis: Osteoporosis" report has been added to ResearchAndMarkets.com's offering. Osteoporosis is the most common metabolic bone disease, and...